CA2257234A1 - Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases - Google Patents

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Info

Publication number
CA2257234A1
CA2257234A1 CA002257234A CA2257234A CA2257234A1 CA 2257234 A1 CA2257234 A1 CA 2257234A1 CA 002257234 A CA002257234 A CA 002257234A CA 2257234 A CA2257234 A CA 2257234A CA 2257234 A1 CA2257234 A1 CA 2257234A1
Authority
CA
Canada
Prior art keywords
disease
diseases
receptor
treatment
neurological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002257234A
Other languages
French (fr)
Other versions
CA2257234C (en
Inventor
Alan L. Mueller
Scott T. Moe
Manuel F. Balandrin
Bradford C. Vanwagenen
Eric G. Delmar
Linda D. Artman
Robert M. Barmore
Daryl L. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
Nps Pharmaceuticals, Inc.
Alan L. Mueller
Scott T. Moe
Manuel F. Balandrin
Bradford C. Vanwagenen
Eric G. Delmar
Linda D. Artman
Robert M. Barmore
Daryl L. Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharmaceuticals, Inc., Alan L. Mueller, Scott T. Moe, Manuel F. Balandrin, Bradford C. Vanwagenen, Eric G. Delmar, Linda D. Artman, Robert M. Barmore, Daryl L. Smith filed Critical Nps Pharmaceuticals, Inc.
Priority to CA002560002A priority Critical patent/CA2560002A1/en
Priority claimed from PCT/US1996/020697 external-priority patent/WO1997046511A1/en
Publication of CA2257234A1 publication Critical patent/CA2257234A1/en
Application granted granted Critical
Publication of CA2257234C publication Critical patent/CA2257234C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
CA002257234A 1996-06-07 1996-12-11 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases Expired - Fee Related CA2257234C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002560002A CA2560002A1 (en) 1996-06-07 1996-12-11 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66301396A 1996-06-07 1996-06-07
US08/663,013 1996-06-07
US9619525 1996-12-06
WOPCT/US96/19525 1996-12-06
PCT/US1996/020697 WO1997046511A1 (en) 1996-06-07 1996-12-11 Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002560002A Division CA2560002A1 (en) 1996-06-07 1996-12-11 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Publications (2)

Publication Number Publication Date
CA2257234A1 true CA2257234A1 (en) 1997-12-11
CA2257234C CA2257234C (en) 2007-01-16

Family

ID=26791398

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257234A Expired - Fee Related CA2257234C (en) 1996-06-07 1996-12-11 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Country Status (1)

Country Link
CA (1) CA2257234C (en)

Also Published As

Publication number Publication date
CA2257234C (en) 2007-01-16

Similar Documents

Publication Publication Date Title
HK1008980A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
EP1123922A3 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CA2260037A1 (en) Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ATE294774T1 (en) AMINOADAMANTAN DERIVATIVES AS THERAPEUTIC AGENTS
CA2244912A1 (en) Novel substituted cyclic amino acids as pharmaceutical agents
CA2339273A1 (en) Branched alkyl pyrrolidine-3-carboxylic acids
HUP9901629A2 (en) Use of r(+)-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
HU9600959D0 (en) Therapeutic agents
CA2257234A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
MX9709911A (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders.
AU3585089A (en) Condensed diazepinones
EP0999204A4 (en) Novel compound having effect of promoting neuron differentiation
EP0934934A3 (en) Methods of preparing substituted 3-phenyl- and 3-pyridyl-4(3H)-quinazolinones and atropisomers thereof
EP0721778A3 (en) NK-1 receptor antagonists for the treatment of neuronal injury and stroke
JO1833B1 (en) Therapeutic agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed